Access RayzeBio Stock and Financial Details

RayzeBio stock price

Forge Price ¹

Price not available

Last Closed Trade ²

Close Date

xx/xx/xx

Last Closed Trade Price

$xx.xx

Last Funding Round (LFR)

Date

xx/xx/xx

Price per Share

$xx.xx

Access Stock Price

RayzeBio funding rounds and valuation

Funding history chart

Funding round details

	Funding Date	Share Class	Amount Raised	Price per Share	Post-Money Valuation	Key Investors
	09/13/2022	Series D	$159.75MM	$xx.xx	$599.64MM	Ally Bridge Group, Laurion Capital Management, Sands Capital, Sofinnova Investments, Soleus Capital, Viking Global Investors, Wellington Management
Price per Share $xx.xx Shares Outstanding 63,972,982 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 8.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors Ally Bridge Group, Laurion Capital Management, Sands Capital, Sofinnova Investments, Soleus Capital, Viking Global Investors, Wellington Management
	06/15/2021	Series C	$99.63MM	$xx.xx	$651.39MM	Acuta Capital Partners, Alexandria Venture Investments, Cg X, Cormorant Asset Management, Deerfield Management, Lifesci Venture Partners, Logos Capital, Orbimed, Perceptive Advisors, Redmile Group, Samsara Biocapital, Venbio Partners, Venrock Healthcare Capital Partners, Versant Ventures, Viking Global Investors, Vivo Capital
Price per Share $xx.xx Shares Outstanding 23,999,996 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.1x Dividend Rate 8.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors Acuta Capital Partners, Alexandria Venture Investments, Cg X, Cormorant Asset Management, Deerfield Management, Lifesci Venture Partners, Logos Capital, Orbimed, Perceptive Advisors, Redmile Group, Samsara Biocapital, Venbio Partners, Venrock Healthcare Capital Partners, Versant Ventures, Viking Global Investors, Vivo Capital
	12/08/2020	Series B	$96.86MM	$xx.xx	$237.83MM	Alexandria Venture Investments, Cormorant Asset Management, Lifesci Venture Partners, Logos Capital, Orbimed, Redmile Group, Samsara Biocapital, Venbio Partners, Venrock Healthcare Capital Partners, Versant Ventures, Viking Global Investors
Price per Share $xx.xx Shares Outstanding 46,666,672 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 8.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors Alexandria Venture Investments, Cormorant Asset Management, Lifesci Venture Partners, Logos Capital, Orbimed, Redmile Group, Samsara Biocapital, Venbio Partners, Venrock Healthcare Capital Partners, Versant Ventures, Viking Global Investors
	10/14/2020	Series A	$41.51MM	$xx.xx	$55.35MM	Samsara Biocapital, Venbio Partners, Versant Ventures
Price per Share $xx.xx Shares Outstanding 45,000,000 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 8.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors Samsara Biocapital, Venbio Partners, Versant Ventures

Access Stock Price

RayzeBio stock FAQs

To buy and sell RayzeBio stock

Can you buy RayzeBio stock?

You can no longer buy RayzeBio stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.

How to buy RayzeBio stock?

Can you sell RayzeBio stock?

You can no longer sell stock of RayzeBio on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.

How to sell RayzeBio stock?

To learn more about RayzeBio stock

Is RayzeBio a public company?

RayzeBio is now a public company.

What is RayzeBio’s stock price?

The stock price of RayzeBio is not currently available.

What is RayzeBio’s stock ticker symbol?

The ticker symbol of RayzeBio is not currently available.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Leadership and board

Leadership

Ken Song, MD

President & Chief Executive Officer

Susan Moran, MD, MSCE

Chief Medical Officer

Arvind Kush

Chief Financial Officer

Kimberly Ma, MS

Senior Vice President, Clinical Operations

Eric Cischoff

Senior Vice President, Development and Operations

Aubrey Haddach, JD

General Counsel & Secretary

Abhi Bhat, PhD

Senior Vice President Chemistry, Head of Discovery

Nicholas Smith, PhD

Senior Vice President, Chemistry Innovation

Gary G. Li, PhD

Senior Vice President, Biology & Translational Medicine

Board

Bong Koh

Venrock

Maha Katabi

Sofinnova Investments

Aaron Kantoff

Investment Partner

Aaron Royston

venBio Partners

Jerel Davis

Versant Ventures

Mike Dybbs

Samsara Capital

RayzeBio news and media highlights

Endpoints News 09/23/2022

With fresh $160M, RayzeBio plots sprint through the clinic for lead radiopharmaceutical program — building on Novartis' success

Ever since its launch in 2020, RayzeBio has talked at length about building a platform company to fulfill the potential that radiopharmaceuticals hold — with seven active programs to boast. But it’s stayed mum about what those programs actually are, instead sticking to updates about new funding, hires or partnerships.

Explore private companies in the BioTech & Pharma sector

Sector: Healthcare

Subsector: BioTech & Pharma

					Last Funding Round
Company		Forge Price	Forge Price Change ⁵	Last Closed Trade	Share Class	Post-Money Valuation	Price per Share	Amount Raised
	Affinia Therapeutics	--	--	$xx.xx	Series B	$365.7MM	$xx.xx	$110MM
	Altos Labs	--	--	$xx.xx	Series C	$6.33B	$xx.xx	$1.5B
	Colossal Biosciences	--	--	$xx.xx	Series C	$10.2B	$xx.xx	$200MM
	Detect	--	--	$xx.xx	Series C-1	$388.91MM	$xx.xx	$75MM
	Egenesis	--	--	$xx.xx	Series D	$332.59MM	$xx.xx	$90.96MM
	Isomorphic Labs	--	--	$xx.xx	--	--	--	--
	Kailera Therapeutics	--	--	$xx.xx	Series A-2 NV	$580.71MM	$xx.xx	$7.09MM
	Loyal	--	--	$xx.xx	Series B-5	$428.44MM	$xx.xx	$17.49MM
	Mammoth Biosciences	--	--	$xx.xx	Series D-2	$1.35B	$xx.xx	$107.74MM
	Precision Neuroscience	--	--	$xx.xx	Series C	$542.69MM	$xx.xx	$102MM

See All Companies

Forge is your trusted partner to buy and sell RayzeBio stock

Forge is the trusted platform for buying and selling private company stock. Investors and shareholders worldwide rely on our deep data insights, liquidity solutions, and tailored investment opportunities to navigate the private market. Register to get started.

First time buying private market stock?

New to selling your private company stock?

Updated on: Mar 12, 2025

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.
Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.

RayzeBio stock